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Summary The concentration of c-erbB-2 oncogene - encoded protein (p185neu) in fresh tumoursamples obtained atthe time of surgery from
94 non-small-cell lung cancer patients (NSCLC) was determined by an enzyme immunoassay. The relative prognostic importance was
estimated, and the influence of other predictors was assessed by means of a Cox's proportional regression model. Median concentration of
p185 in tumour tissues was 206 U mg-' (range 21-1050 U mg-'). p185 level did not differ significantly among subgroups defined by TNM
classification, histological type, sex and age. Categorization of patients by p185 level, with 206 U mg-' and 343 U mg-1 taken as cut-off values
(corresponding to the 50th and 80th percentiles of the frequency distribution), showed that the recurrence rate, cumulative disease-free
likelihood at the 36-month follow-up and median time from surgery to the diagnosis of recurrence worsened progressively as the level of p185
increased. Multivariate analysis confirmed the independent prognostic value of p185 level. Risk of recurrence increased by 1.304 for every
increase of 100 units in p185 concentration (95% Cl 1.141-1.490) (P<0.001). These findings encourage the inclusion of p185 concentration
assay in a future predictive multifactorial prognostic index in NSCLC.
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The c-erbB-2 proto-oncogene (also calledHER-21neu) is a member
of the erbB-like oncogene family, mapped on chromosome 17 at
q21 (Drebin et al, 1984; Fukushige et al, 1986). It encodes a
membrane glycoprotein (pl85neu) that functions as a growth
factor receptor. p185 protein seems to play a role in regulating
epithelial cell growth (Coussens et al, 1985; Stern, 1986).
Overexpression of p185 has been reported in up to 30% of non-
small-cell lung carcinomas (NSCLC) (Kern et al, 1990; Weiner et
al, 1990; Tateishi etal, 1991; Shi et al, 1992; Bongiorno et al, 1994;
Kern et al, 1994; Harpole etal, 1995). Several reports point to over-
expression ofthis protein as being an independent prognostic factor
associated with unfavourable post-operative outcome (Stern,
1986). Evaluation ofp185 expression may be a good candidate for
inclusion in a hypothetical future multifactorial index for esti-
mating post-operative NSCLC prognosis (Harpole et al, 1995).
To date, p185 protein has been evaluated by immunohistochem-
ical methods or Western blot analysis. The former provide only
semiquantitative results and are associated with a certain degree of
interobserver variation. Western blot analysis is too cumbersome
and time-consuming to be used for large-scale patient series.
Quantification of p185 protein by an enzyme immunoassay has
recently become available. Theoretically, this assay offers very
valuable characteristics (Fielding et al, 1992), rendering it a good
candidate for introduction in clinical medicine for assessment ofc-
erbB-2 expression. However, before introducing this technique as
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an alternative and/or complement to currently available methods,
more data are needed on the performance characteristics of the
test, and the clinical information yielded. The present study was
designed to determine the concentration of p185neu protein in
fresh samples of NSCLC tissue and to assess the relationship
between p185 level and tumour recurrence.
MATERIALS AND METHODS
Study population
All patients with non-small-cell carcinoma ofthe lung, who under-
went tumour resection with curative intent during the period
October 1990 to October 1993 were considered for inclusion in the
study. Resection was judged curative when the primary tumour
mass was excised along with all positive hilar and mediastinal
lymph nodes and with histologically proven negative margins. An
additional seventeen patients who underwent lung tumour resec-
tion during the above period were excluded from the study for the
following reasons: chemotherapy or radiation therapy before
surgery (eight patients); death due to post-surgery complications
(six patients); and inadequate amount of tissue available for p185
study (three patients). The study population comprised 94 histo-
logically proven NSCLC patients (85 men and nine women, mean
age 62 years, s.d. 9 years). All patients were consecutively studied
and followed up prospectively. Histopathological diagnosis was
carried out in accordance with the WHO classification of lung
tumours (World Health Organization, 1982): 61 patients (65%)
had squamous carcinoma, 27 (29%) had adenocarcinoma and six
(6%) had large-cell carcinoma. Tumour-node-metastasis (TNM)
(Mountain, 1986) staging was performed by correlating the opera-
tive and histological findings: 52 patients (55.5%) were in stage I,
eight (8.5%) were in stage II and 34 (36%) were in stage IIIA. All
patients underwent preoperative bronchoscopy, chest radiography
and thoracoabdominal computerized tomographic (CT) scan.
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Mediastinoscopy was not routinely performed. Head CT scans and
radionuclide scans of liver or bone were performed only when
indicated by clinical or biochemical abnormalities. During
surgery, careful complete sampling of ipsilateral mediastinal
lymph node groups was routinely performed on all patients before
resection ofthe primary lesion.
Tumour recurrence was diagnosed in 43 (45%) patients, 40 of
whom have since died. Follow-up was completed in 89 patients
(94.6%). During follow-up, two patients died from unrelated
causes and two patients were lost to follow-up; none ofthese cases
showed evidence ofrecurrence. Follow-up time ranged from 11 to
57 months, with a median of 28 months. Median time to recur-
rence was 20 months. Cumulative likelihood of 3-year disease-
free survival was 47% (95% CI 35-58).
Thirteen patients who underwent surgical treatment for idio-
pathic pneumothorax were included to establish a p185 expression
reference control level. This group comprised five women and
eight men with a mean age of 25 years (s.d. 7 years).
Tissue preparation
Lung samples were obtained from all patients at the time of
surgery. The excised lung specimens were divided, one piece
being sent for histological examination and a second piece, 1 cm3
in size, being taken for p185 assay. The latter pieces were split of
any necrotic tissue, washed with ice-cold saline and immediately
frozen in liquid nitrogen until assayed. In no case were tissue
samples stored for more than 3 months before analysis. Tests had
previously shown these samples to have a minimum 80%
neoplastic cell content. For assay purposes, the frozen specimens
were weighed and pulverized to fine powder with a cryogrinder
while maintained in liquid nitrogen. The tissue powder was
suspended in Tris buffer - 10 mmol of Tris base, 1.5 mmol 1-1
EDTA, 5 mmol 1-' natrium molybdate, 100 ml monothioglycerol.
Homogenization was performed by three 15-s strokes at 1400
r.p.m., at a constant temperature of 4°C. The mixture was then
centrifuged at 2000 r.p.m. and the supernatant ultracentrifued at
100 000 g for 60 min at 4°C. The clear supernatant fraction
(cytosol) was used for p185 assay.
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p185 protein assay
p185 was determined by using a commercially available assay
(Oncogene Science, Uniondale, NY, USA). This is a sandwich
enzyme immunoassay that uses two antibodies raised against the
extracellular domain of p185 (McKenzie et al, 1989). Volumes of
100 ,ul of each cytosol sample were dispensed in duplicate onto a
96-well microplate. The first antibody (NB3) immunoadsorbed on
microplate was used to capture solubilized p185. The second
biotinylated rabbit policlonal antibody bound to the immobilized p
185 was measured by complexing it with a steptavidin-horse-
radish peroxidase conjugate, which then catalyses the conversion
of the chromogenic substrate o-phenylendiamine into a coloured
product. The concentration of standard antigens ranged from 10 to
120 U ml 1(1 U ml- = 0.05 fmol ml-'). Total protein concentration
was measured by the Lowry method. Samples were diluted before
p185 determination to ensure a total protein concentration of
2-4 mg ml-. p185 results were expressed as units per milligram
(U mg-') ofprotein.
Performance characteristics of the assay
Three lung cancer samples were homogenized and ultracen-
trifuged, and five aliquots of 50 ,ul of each tissue extract were
collected and treated as independent specimens. Mean p185
concentration for these three patients were 35,256 and 578 U mg-'.
Intra- and inter-assay coefficients of variation (CVs) were 6% and
9% respectively. Accuracy was evaluated by using a dilution test.
The method yielded linear results (expected value = -0.48 + 1.02
calculated value, r = 0.95) ranging from 98 to 11 U ml' of p185
concentration. Method sensitivity was set at 0.2 U ml-'.
Immunohistochemistry
In order to validate the ELISA technique, 40 tumours were assayed
simultaneously for p185 expression by immunohistochemistry. The
results yielded by both methods were then compared. Paraffin-
embedded blocks from the tumour were cut, dewaxed and rehy-
drated through graded alcohols. Following inhibition ofendogenous
peroxidase, the monoclonal antibody to p185neu protein, NCL-CB11
(Novocastra, Newcastle upon Tyne, UK) was applied at adilution of
1:20, and sections were incubated overnight. Secondary antibody,
rabbit anti-mouse immunoglobulin (Dakopatts, Golstrup, Denmark)
was applied at a dilution of 1:200 for 40 min at room temperature.
Sections were then rinsed with Tris-buffered saline (TBS) and incu-
bated in the avidin-biotin complex (Dakopatts, Golstrup, Denmark)
for 30 min. Diaminobenzidine was used as chromogen and haema-
toxylin as nuclear counterstain. With each batch, both positive and
negative controls were included. For interpretation of the immuno-
histochemistry, membrane or membrane and cytoplasmic reactivity
were considered to be positive. Staining was semiquantitated as
follows: 0, no staining; 1, weak staining; 2, strong staining.
Statistical analysis
I
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Figure 1 Frequency distribution of p185 protein concentration in lung cancer
tissue
Median and interquartile distances were used as summary measures
owing to the asymmetric distribution ofp185. The concentration of
p185 was stratified according to sex, age group, histological type
and TNM stage. For two-group comparisons we used the non-para-
metric Wilcoxon test. Levels in different categories were compared
by means of the Kruskal-Wallis test. Disease-free survival was
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Table 1 p185 level in tumour tissue categorized by patients' characteristics
n Mean (s.d.) Median (p25-pP75) P-value
Total 94 258.2 (206.2) 206.0 (111.5-306.5)
Histological type 0.4167
Squamous 61 232.7 (170.1) 186.0 (106.5-285.3)
Adenocarcinoma 27 298.8 (232.5) 250.5 (132.0-329.0)
Large-cell carcinoma 6 335.3 (372.1) 202.0 (63.0-317.0)
TNM stage 0.9754
52 265.3 (219.2) 240.0 (102.0-290.0)
11 8 226.9 (145.1) 163.0 (110.0-206.0)
Illa 34 254.8 (201.9) 198.0 (116.5-330.5)
Sex 0.5205
Male 85 254.6 (203.4) 202.3 (109.3-307.8)
Female 9 292.7 (241.6) 230.0 (123.3-300.5)
Age 0.2124
<65 55 275.5 (210.6) 234.0 (118.3-325.3)
<65 39 233.9 (200.0) 159.5 (99.8-288.5)
Table 2 Predictors of disease-free survival in non-small-cell lung cancer according to the univariate analysis
Variable No. of No. of Survival (months) Hazard ratio 95% Cl P-value
patients events
6 12 18 24 30 36
Histological type
Squamous 61 28 95 71 55 48 48 48 1
Adenocarcinoma 27 10 85 77 68 56 56 56 0.79 0.38-1.65 0.528
Large-cell carcinoma 6 4 50 33 33 33 33 33 3.40 1.25-9.27 0.017
TNM stage
52 18 96 85 70 61 61 56 1
11 8 4 88 63 47 47 47 47 1.86 0.61-5.61 0.274
Illa 34 21 78 50 39 31 31 31 2.62 1.38-5.00 0.003
Sex
Male 85 38 89 70 58 50 50 48 1
Female 9 5 89 78 56 44 44 44 1.04 0.40-2.68 0.943
Age (years)
<65 57 24 88 73 63 54 54 50 1
<65 37 19 91 66 49 42 42 42 1.42 0.77-2.63 0.261
pl85neu(U mg 1)
<206 47 17 91 80 73 61 61 56 1
.206 and <343 28 14 93 71 53 47 47 47 1.46 0.71-3.00 0.304
>343 19 12 78 44 25 25 25 25 3.02 1.39-6.54 0.005
defined as from date of operation to date of recurrence or last
follow-up. The relationship between the cumulative probability of
recurrence and thepredictors analysed (age, sex,TNM,histological
type, p185 level) was determined via the Kaplan-Meier method,
and statistically significant differences were checkedwiththe aid of
Mantel's log-rank test. The relative importance of multiple prog-
nostic factors on disease-free survival was estimated by means ofa
Cox's proportional regression model (Cox, 1972). Two-way inter-
action effects betweenp185 concentration and other variables were
assessed. For the final model, the assumption of proportional
hazards was confirmed both graphically (Miller, 1981) and by
introducing the interaction ofp185 level with the log of time as a
time-dependent covariable (Breslow et al, 1987).
RESULTS
Description of p185 concentration
Concentration ofp185 in tumour tissue ranged from 21 to 1050 U
mg-',with a median value of206 U mg-' (25th and 75thpercentiles
were 111 and 306 U mg-' respectively). A graphical representation
of the frequency distribution ofp185 levels is shown in Figure 1.
Distribution of values was positively skewed. Observation of the
histogram allows two populations to be discerned, with 400 U mg-'
acting as the cut-off point. On the left, 84% of tumour samples
plotted a near-normal distribution, ranging from 21 to 343 U mg-',
with a median value of 200 U mg-1. On the right lies the group of
patients with the highest p185 values, with the frequency distribu-
tion ofconcentrations forming a long plateau.
Concentration of p185 and distribution of results by patients'
characteristics are shown in Table 1. p185 level did not differ
significantly among subgroups defined by TNM classification,
histological type, sex and age. Adenocarcinomas and large-cell
carcinomas showed higher concentrations than squamous carci-
nomas, but the difference did not reach statistical significance.
When adenocarcinomas and large-cell carcinomas were grouped
together, the comparison with squamous carcinomas showed
borderline significance (P=0.08).
Concentration ofp185 in lung tissue frompatients with idiopathic
pneumothorax ranged from 52 to 240 U mg-', with a median value
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Table 3 Kaplan-Meier estimates of disease-free survival for the different predictor variables stratified according to p185 level
Variable No. of No. of Survival (months) PLvalue
patients events
6 12 18 24 30 36
Histological type
Squamous + adenocarcinoma
pl85neu < 206 U mg-' 44 14 93 84 76 62 62 62 0.024
p185- >2 206 U mg-' 44 24 91 63 44 40 40 40
Large-cell carcinoma
p185ne < 206 U mg-1 3 2 67 33 33 33 33 33 0.946
pl85neu> 206 U mg-' 3 2 33 33 33 33 33 33
TNM stage
p185neu<2O6Umg-' 24 6 100 96 91 70 58 58 0.153
pl85neu.206 U mg-' 28 12 93 75 55 55 55 55
11 + IIIA
p185neu < 206 U mg-1 23 11 92 64 54 49 49 49 0.076
pl85neu.206 U mg-' 19 14 78 39 23 12 12 12
Sex
Male
pl85neu< 206 U mg-' 43 16 91 79 70 60 60 54 0.133
pl85neu.206 U mg-' 42 22 89 61 46 41 41 41
Female
pl85neu< 206 U mg-' 4 1 100 100 100 75 75 75 0.061
p185- 2206 U mg-' 5 4 80 60 20 20 20 20
Age (years)
<65
p185n" < 206 U mg-' 24 7 92 88 83 70 70 59 0.062
pl85neu.206 U mg-' 32 17 84 63 48 43 43 43
<65
pl85neu< 206 U mg-' 22 10 91 71 61 50 50 50 0.222
pl85neu.206 U mg-' 15 9 93 57 29 29 29 29
of 113 U mg-' (25th and 75th percentiles were 99 and 162 U mg-'
respectively). Mean p185 concentration in this group was signifi-
90 tj cantly lower than that found inlung cancer tissue (125 ± 54 Umg-'
vs 256 ± 206 U mg-') (P<0.001). Taking the highest value found in
the idiopathic pneumothorax group (240 U mg-1) as cut-off, we
80 8 found that 41 (43.6%) NSCLC tumours registered high p185 levels.
70 '*1 (>a 70 7 Analysis of predictive value
Univariate analysis showed that cumulative disease-free survival
60 was related to TNM status, p185 concentration and histological
type (Table 2). Analysis of disease-free survival by p185 was
50 affected by categorizing patients according to protein concentra-
-tion. The 50th and 80th percentiles of the frequency distribution
(206 U mg' and 343 U mg-1 respectively) were taken as cut-off
40 values. The recurrence rate increased in direct proportion to p185
concentration: 36% (17/47) for p185 levels below 206 U mg-';
30- 50% (14/28) for p185 levels between 206 and 343 U mg-'; and
63% (12/19) for p185 levels over 343 U mg' (P=0.11). Median -................. .time from surgery to diagnosis of recurrence was 11 months in
20 __.........__.......__II_II__II__II __I- __ patients in the high-level group and 21 months among those in the
0 10 20 30 40 50 60 70 intermediate group. Median time for patients with low-level p185
Months has not yet been reached. Thirty-six month cumulative disease-
free survival probability was 25% (95% CI 6-51) in the high-level Figure 2 Thirty-six-month cumulative disease-free survival probability by
p185 level. <206,u mg-'; 206-343,u mg-';...... >343j mg-1. (log-rank group, 47% (95% CI 27-65) in the intermediate group and 56%
test, P= 0.017) (95% CI 37-71) in the low-level group (P=0.017) (Figure 2).
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Table 4 Predictors of disease-free survival in non-small-cell lung cancer
according to the multivariate analysis
Hazard
Variable ratio 95% Cl P-value
Histological type
Squamous+adenocarcinoma 1
Large-cell carcinoma 5.009 1.583-15.350 0.005
TNM stage
1
11+IIA 3.030 1.583-5.798 <0.001
Age (years)
<65 1
>65 1.834 0.965-3.485 0.064
p1 85neu protein
for every 100 U 1.350 1.163-1.567 <0.001
Stratification for other variables did not change the predictor value
of p185 (Table 3). For all categories, the best results were regis-
tered by patients with lowest p185 levels, but small numbers
prevented the study from having sufficient statistical power to
attain significance at a 95% CI level.
Results of the multivariate model are set out in Table 4.
Squamous carcinomas and adenocarcinomas were taken as the
reference group for histological type as, in the univariate analysis,
these categories displayed no differences vis-'a-vis likelihood of
relapse. Similarly, stages II and Illa were analysed jointly. In the
final model, p185 was deemed a continuous variable, thereby
avoiding adoption ofarbitrary cut-offs. p185 level revealed itselfto
be an independent predictive factor. Risk of recurrence increased
by 1.35 for every increase of 100 units in the concentration ofp185
(95% CI 1.141-1.490, P<0.001).
Graphical analysis did not show any violation of the propor-
tional hazards assumption, and the interaction between exposure
and time was not significant. This latter result implies that, for the
follow-up period considered, p185 concentration did not lose its
predictor value with time.
Comparison between ELISA and
immunohistochemistry
Positive reactivity to p185 was detected by immunohistochemistry
in 16 (40%) of the 40 tumours in which p185 expression was
assessed by both methods. For tumours showing p185 overexpres-
sion by immunohistochemistry, mean p185 concentration regis-
tered by ELISA (356 U mg-1, s.d. = 96) was significantly higher
than for negative tumours (145 U mg-', s.d.=74, P<0.001). Of the
24 samples which tested negative with immunohistochemistry,
only two registered ELISA-based levels above cut-off (240 U
mg-'). Furthermore, of the 16 samples that tested positive with
immunohistochemistry, only one yielded and ELISA-based level
lower than cut-off. Correlation between the two methods was good
(r=0.85, P<0.01).
DISCUSSION
Our data show that c-erbB-2 expression is an independent prog-
nostic factor for tumour recurrence in resectable NSCLC. The
main contribution of our study is to show that post-operative
outcome figures and risk ofrecurrence worsen proportionally with
a rise in p185 levels in tumour tissue. We have observed that eval-
uation of p185 expression as a continuous variable enables the
predictive information of this marker to be more efficiently
exploited than ifanalysed as a dichotomous variable.
Risk ofrecurrence increases by 1.304 for every 100 U mg-' rise
in the p185 level. According to the results obtained in the multi-
variate analysis, TNM staging and histological type are the most
important predictive variables for patients with p185 levels lower
than 100 U mg-'. As p185 concentration increases, however, the
risk attributed to this marker increases too. In patients with p185
levels over 600 U mg-', the negative influence of the protein
becomes even more important than the influence of TNM staging
and histological type. This fact underscores the need to avoid
dichotomous results (positive vs negative), at least in those cases
in which such a marker is employed for assessing the prognosis.
Although a cut-off point is occasionally used to define a high- or
low-risk group ofpatients, this approach tends to oversimplify and
even distort the relationship between variables and outcome.
Predictive multivariate models can be used on a case-by-case
basis to calculate risk of post-operative recurrence. Using the
hazard ratios, one could estimate the risk of recurrence for any
patient by multiplying the ratios for all factors present. An
example ofthis would be a calculated risk for a patient with stage
Illa squamous carcinoma and p185 concentration of 350 U ml-',
nine-fold higher (1.304 x 1.304 x 1.304 x 4.063 x 1) than for a
patient with stage I squamous carcinoma and p185 under 100 U
ml-'. The possibility of individualized patient management based
on p185 levels and, in particular, that of tailoring adjuvant
chemotherapy to high-risk patients is an attractive prospect. A
treatment protocol could be constructed, with patients being strati-
fied according to a given calculated risk vis-a-vis the overall popu-
lation. Those patients at high risk for recurrence and death would
receive adjuvant chemotherapy. However, in vitro and clinical
studies would first have to investigate the ideal chemoradiation
therapy for tumours expressing the marker. At present, in vitro
studies with NSCLC cell lines show that c-erbB-2 overexpressing
tumours are less likely to respond to standard doses of chemo-
therapy (Tsai et al, 1995). Adequate agents and programmes
should be defined.
We cannot clearly define a diagnostic cut-off value from our
data. Immunohistochemically based studies show that 30-40% of
NSCLC tumours react positively to anti-p185 staining (Harpole et
al, 1995; Kern et al, 1990; 1994; Shi et al, 1992; Tateishi et al,
1991; Weiner et al, 1990). According to the frequency distribution
of our series, the proposed cut-off furnishes a percentage of posi-
tivity for tumour tissue similar to that yielded by immunohisto-
chemically based studies. Our cut-off corresponds to the highest
concentration found in the idiopathic pneumothorax group.
However, further studies using normal lung and non-malignant
tissue from patients with lung cancer are needed to clearly define
the normal range of values for p185 concentration, something
which at present remains unknown.
On the other hand, our data confirm the feasibility of the
enzyme immunoassay for p185. Not only did it show good accu-
racy and precision, but the technique itself is simple and repeat-
able. Results are expressed in a manner that is both objective and
comparable and can be put at the clinician's disposal within a very
short space of time. These features facilitate routine use of the
assay in clinical medicine. In addition, sensitivity is very high so
that, theoretically, the test may be performed on material from
bronchoscopic biopsies as well.
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Recently published reports indicate that there is a close relation-
ship between the enzyme immunoassay for p185 and immunohis-
tochemistry (Cuny et al, 1994; Dittadi et al, 1992; Narita et al,
1994; Nugent et al, 1994). Both techniques can be seen as comple-
mentary methods for assessing tissue parameters. While immuno-
histochemical testing gives the tissue distribution of the examined
parameter, biochemical methods provide an integrated and quanti-
tative analysis.
The current study shows that p185 concentration is an objective
and comparable parameter for assessing NSCLC tumour-pheno-
type aggressiveness. In future, a score derived via a multiple-
regression approach, combining the TNM classification system for
anatomic description oftumour spread and one or several parame-
ters for the assessment of tumour aggressiveness, may generate a
patient-specific prognostic index. p185 assay is a good candidate
for inclusion in such a multifactorial predictive model.
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